Looking at Real-World Data Supporting Durvalumab in NSCLC

May 26, 2023

In a new Targeted Oncology Case-Based Roundtable, clinicians discussed new real-world data (RWD) supporting the use of durvalumab in unresectable stage III non-small cell lung cancer (NSCLC). The clinicians discussed their use of the immunotherapy, noting that most of them continued the treatment for 12 months, the length of treatment used in the observational study.

According to Edward S. Kim, MD, MBA, “I think 12 months is the goal, and I wouldn’t go past 12 months. We’re all tempted by that especially when the patient looks good. It is the same thing in the metastatic setting when we’re giving maintenance. What do you do when you stop? It’s hard to say, but the study used 12 months so I would just use 12 months and then let patients go at that point and follow them with scans. Short of some of immune-related AEs like interstitial lung disease and others, [which] we know how to manage through, we want to keep going. It doesn’t surprise me that the real-world data shows it’s a little bit better because I think [physicians] are more comfortable.”

To read more, click here.